Stanford University professor Michelle Mello argued in a JAMA Health Forum commentary that Doctronic's contract is legally murky regarding liability for potential AI-based prescribing errors.

Overview Debates Related claims Topics Sources

Inquiry chair Kate Lampard is considering issuing interim regulations and recommendations regarding Oxevision camera technology to prevent further avoidable patient deaths.

The Medicines and Healthcare products Regulatory Agency requested clinical evidence from manufacturer Lio Health supporting claims that Oxevision reduced self-harm, but Lio Health failed to provide it.

Lawyers representing over 70 bereaved families urged the Lampard Inquiry on October 20, 2026 to recommend a national ban on Oxevision in NHS mental health inpatient wards.

NHS England stated that legal and operational responsibility for deploying and operating the Oxevision camera system rests entirely with individual NHS foundation trusts.

India's Central Drugs Standard Control Organisation requires artificial intelligence developers to demonstrate clinical validity, demographic diversity in training datasets, version control, and post-market surveillance plans.

India's Central Drugs Standard Control Organisation issued guidance in July 2026 establishing approval pathways for Software in a Medical Device and Software as a Medical Device.

Regulatory sandboxes allow health authorities to evaluate rapidly evolving artificial intelligence technologies and balance patient safety against clinical innovation.

A joint report by European science academies proposed regulatory sandboxes as controlled, time-limited environments to test medical artificial intelligence tools under regulatory oversight before clinical deployment.

Sound Practice 10 of the Financial Stability Board's guidance establishes a risk-based intervention model requiring mandatory human sign-off for financial transactions exceeding specific thresholds.

The Financial Stability Board published 12 non-binding recommended practices on October 16, 2026, for the responsible adoption of artificial intelligence in financial institutions across G20 economies.

US regulatory guidance OCC Bulletin 2026-13, issued jointly by the OCC, Federal Reserve Board, and FDIC on April 17, 2026, explicitly excluded generative and agentic AI models from its scope.

The American Medical Association's framework focuses on four questions covering clinical functions, evidence of performance, conditions of permission, and risk accountability.

The Financial Stability Board declined to framing AI systems as synthetic employees, citing concerns that the analogy obscures unpredictable autonomous decisions.

The American Medical Association released a new governance framework on October 15, 2026, to guide the safe deployment of agentic AI assuming clinical functions in healthcare.

EHR vendors should be required to provide open access to third-party AI tools

The Lancet series authors call for coordinated international regulation of technology business models, safety standards for platform design, and independent oversight of AI harms to youth.

To address legal ambiguities, the Office of Artificial Intelligence Policy requires a special malpractice insurance covering AI-generated prescriptions and builds specific duty of care provisions into contracts.

Utah's Artificial Intelligence Learning Laboratory, or AI sandbox, was established by state law in 2024 to allow the Office of Artificial Intelligence Policy to waive regulations for testing AI products.

The Nolla Health pilot was amended to include a third-party physician appointed by the Utah Medical Licensing Board to oversee prescription reviews.

Utah's Office of Artificial Intelligence Policy approved a plan on October 5, 2026, allowing an artificial intelligence product to evaluate patients and write new drug prescriptions without direct human oversight.